Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 108

Results For "trial"

2303 News Found

Strides Pharma Science appoints Dr. C. Muthulingam as Executive VP - R&D
People | November 22, 2024

Strides Pharma Science appoints Dr. C. Muthulingam as Executive VP - R&D

Dr. Muthu was last associated with Mankind Pharma


Azenta obtains regulatory approval for clinical long-read whole genome sequencing test
Biotech | November 22, 2024

Azenta obtains regulatory approval for clinical long-read whole genome sequencing test

Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory


Converge Bio raises $5.5M Seed to speed up drug discovery and development with Generative AI
Digitisation | November 22, 2024

Converge Bio raises $5.5M Seed to speed up drug discovery and development with Generative AI

Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion


Tagrisso recommended for approval in the EU for unresectable EGFR-mutated lung cancer
Drug Approval | November 19, 2024

Tagrisso recommended for approval in the EU for unresectable EGFR-mutated lung cancer

Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years


Merck receives positive EU CHMP opinion for pembrolizumab plus chemotherapy as first-line treatment for unresectable non-epithelioid MPM
Drug Approval | November 16, 2024

Merck receives positive EU CHMP opinion for pembrolizumab plus chemotherapy as first-line treatment for unresectable non-epithelioid MPM

Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial


Lubrizol and Polyhose ink MoU to set up medical tube manufacturing facility in Tamil Nadu
News | November 15, 2024

Lubrizol and Polyhose ink MoU to set up medical tube manufacturing facility in Tamil Nadu

This agreement reinforces Lubrizol’s commitment to Make-In-India and broadens a previously committed US$ 350 million investment to support local manufacturing


AbbVie provides update on Phase 2 results for Emraclidine in schizophrenia
News | November 14, 2024

AbbVie provides update on Phase 2 results for Emraclidine in schizophrenia

Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial


Lonza’s Synaffix collaborates with BigHat Biosciences for ML-designed ADC
News | November 05, 2024

Lonza’s Synaffix collaborates with BigHat Biosciences for ML-designed ADC

Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies


AbbVie to acquire Aliada Therapeutics
News | November 01, 2024

AbbVie to acquire Aliada Therapeutics

Strengthening focus in Alzheimer's disease and neuroscience pipeline